About us

Our name Enara Bio™ is derived from an Arabic word meaning illumination, enlightenment and bringing light into the darkness.

We are the leaders in exploring the hidden depths of cancer and T-cell biology to discover and characterize Dark Antigens™, a novel class of shared immunotherapy targets that arise from altered cellular processes in cancer cells. We believe that Dark Antigens have the core attributes that will enable cancer immunotherapies to improve treatment outcomes for broad patient populations.

Enara Bio is backed by prominent life science investors, including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital and SV Health Investors. We collaborate with world-leading companies and academic institutions, such as Boehringer Ingelheim and the Francis Crick Institute, to help drive our differentiated science-led approach.